Valuation: Genmab A/S

Market Cap 121B 18.65B 16.17B 15.16B 13.82B 26B 1,780B 26.42B 178B 69.67B 891B 70.03B 68.51B 2,973B P/E 2026 *
25.6x
P/E 2027 * 18x
Enterprise Value 141B 21.68B 18.79B 17.62B 16.06B 30.22B 2,069B 30.71B 207B 80.98B 1,036B 81.39B 79.63B 3,455B EV / Sales 2026 *
4.84x
EV / Sales 2027 * 3.92x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day+0.30%
1 week+1.80%
Current month+9.50%
1 month+9.41%
3 months+20.38%
6 months+8.77%
Current year+0.39%
1 week 1,958.5
Extreme 1958.5
2,043
1 month 1,819.5
Extreme 1819.5
2,066
Current year 1,512
Extreme 1512
2,257
1 year 1,472
Extreme 1472
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%+1.80%+39.53%-19.72% 18.65B
+2.07%+13.76%+65.44%+106.53% 71.56B
-1.27%-2.41%+33.81%+62.94% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
-5.38%-0.59%+35.86%+195.96% 11.72B
Average -1.09%+3.60%+51.43%+201.59% 27.82B
Weighted average by Cap. -0.54%+3.46%+50.17%+164.59%

Financials

2026 *2027 *
Net sales 29.01B 4.48B 3.88B 3.64B 3.32B 6.24B 427B 6.34B 42.82B 16.72B 214B 16.8B 16.44B 713B 33.71B 5.2B 4.51B 4.23B 3.85B 7.25B 496B 7.37B 49.76B 19.43B 248B 19.53B 19.1B 829B
Net income 4.94B 762M 661M 619M 565M 1.06B 72.75B 1.08B 7.29B 2.85B 36.42B 2.86B 2.8B 121B 7.17B 1.11B 959M 899M 820M 1.54B 106B 1.57B 10.59B 4.13B 52.87B 4.15B 4.06B 176B
Net Debt 19.62B 3.03B 2.62B 2.46B 2.24B 4.22B 289B 4.29B 28.96B 11.31B 145B 11.36B 11.12B 482B 11.13B 1.72B 1.49B 1.4B 1.27B 2.39B 164B 2.43B 16.43B 6.41B 82.03B 6.45B 6.31B 274B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-14 DKK 2,035.00 +0.49% 12,738
26-08-13 DKK 2,025.00 -0.59% 103,599
26-08-12 DKK 2,037.00 +2.21% 133,012
26-08-11 DKK 1,993.00 +0.05% 87,351
26-08-10 DKK 1,992.00 -0.35% 129,558
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,025.00DKK
Average target price
2,410.59DKK
Spread / Average Target
+19.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock